Explore
Validate
Learn
Immunocytochemistry
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Immunohistochemistry [1]
- Chromatin Immunoprecipitation [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA022236 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA022236, RRID:AB_2670915
- Product name
- Anti-CHD1
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human CHD1, Gene description: chromodomain helicase DNA binding protein 1, Validated applications: ChIP, ICC, IHC, Uniprot ID: O14646, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.2 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2
Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer
Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression
Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer
Li H, Wang Y, Lin K, Venkadakrishnan V, Bakht M, Shi W, Meng C, Zhang J, Tremble K, Liang X, Song J, Feng X, Van V, Deng P, Burks J, Aparicio A, Keyomarsi K, Chen J, Lu Y, Beltran H, Zhao D
Cancer Research 2022;82(17):3088-3101
Cancer Research 2022;82(17):3088-3101
Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer
Zhao D, Cai L, Lu X, Liang X, Li J, Chen P, Ittmann M, Shang X, Jiang S, Li H, Meng C, Flores I, Song J, Horner J, Lan Z, Wu C, Li J, Chang Q, Chen K, Wang G, Deng P, Spring D, Wang Y, DePinho R
Cancer Discovery 2020;10(9):1374-1387
Cancer Discovery 2020;10(9):1374-1387
Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression
Ormond D, Kleinschmidt-DeMasters B, Cavalcante D, Smith E, Cramer S, Lucia M
Journal of Neuro-Oncology 2019;142(2):319-325
Journal of Neuro-Oncology 2019;142(2):319-325
Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer
Zhao D, Lu X, Wang G, Lan Z, Liao W, Li J, Liang X, Chen J, Shah S, Shang X, Tang M, Deng P, Dey P, Chakravarti D, Chen P, Spring D, Navone N, Troncoso P, Zhang J, Wang Y, DePinho R
Nature 2017;542(7642):484-488
Nature 2017;542(7642):484-488
No comments: Submit comment
Supportive validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Orthogonal validation
- Main image
- Experimental details
- Immunohistochemistry analysis in human testis and skeletal muscle tissues using HPA022236 antibody. Corresponding CHD1 RNA-seq data are presented for the same tissues.
- Sample type
- Human
- Protocol
- Protocol
Supportive validation
- Submitted by
- Atlas Antibodies (provider)
- Main image
- Experimental details
- ChIP-Exo-Seq composite graph for Anti-CHD1 (HPA022236, Lot 000008248) tested in K562 cells. Strand-specific reads (blue: forward, red: reverse) and IgG controls (black: forward, grey: reverse) are plotted against the distance from a composite set of reference binding sites. The antibody exhibits robust target enrichment compared to a non-specific IgG control and precisely reveals its structural organization around the binding site. Data generated by Prof. B. F. Pugh´s Lab at Cornell University.
